1206P HER2 copy number variation (CNV), HER2 expression and primary resistance mechanisms in patients (pts) with HER2-positive metastatic gastric or gastroesophageal junction cancer (mGC/GEJC) receiving first-line chemotherapy (CT) + trastuzumab (T) +/- pertuzumab (P) in the JACOB trial
| Autor: | Pietrantonio, F., Berrino, E., Manca, P., S.E. Bellomo, Raimondi, A., Corso, S., Morano, F., Migliore, C., Niger, M., Marchiò, C., Di Bartolomeo, M., Restuccia, E., Lambertini, C., Tabernero, J., Giordano, S. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1100-S1101 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|